Drug Updates

Update on: Tretinoin gel 0.1% Retin-A Micro® Delavirdine Rescriptor® Nelfinavir Viracept®Calcipotriene ointment Dovonex® Valacyclovir tablet Valtrex®Pulsed Er:Yag laser system Derma 20®Human skin equivalent Apligraf®Podofilox gel 0.5% Condylox®

Update on: Efavirenz Sustiva® Nevirapine Viramune®Famciclovir Famvir®Cetirizine Zyrtec® Rifapentine Priftin® Denileukin diftitox Ontak® Doxorubicin Caelyx® Graftskin Apligraf® Dangers of alternative medicine, Protease inhibitors during pregnancy

Update on Polymethylmethacrylate/ Bovine Collagen ArteFill® Artes Medical, Polyphenon® E Ointment 15% MediGene AG/ Bradley Pharmaceuticals, and drug news on melanoma and new vaccines.

Update on Terbinafine hydrochloride Lamisil® Novartis Pharmaceuticals, Famciclovir TEVA Pharmaceutical Industries, Ceftobiprole BAL5788 Basilea Pharmaceutica/Janssen-Ortho.

Update on Tofacitinib citrate tablets (Xeljanz®), Lidocaine 7% + tetracaine 7% cream (Pliaglis®), Calcipotriene 0.005% + betamethasone dipropionate 0.064% topical suspension (Taclonex®), Tocilizumab (Actemra®), C1 esterase inhibitor (human) (Cinryze®), and Doxycycline monohydrate 40 mg capsules (Apprilon®)

Update on Brimonidine tartrate 0.33% topical gel (Onreltea®Mirvaso®), Apremilast tablets (Otezla®), Miltefosine capsules (Impavido®), Hydrogel wound dressing (Loutrex®), Omalizumab for SC injection (Xolair®), Propranolol hydrochloride oral solution (Hemangeol™), Microbicide-coated condom Vivagel® (SPL7013 gel)

Update on Drugs & Devices May and June 2018: Tildrakizumab-asmn for SC injection Ilumya™, Lidocaine topical system 1.8% for postherpetic neuralgia ZTlido™, Secukinumab for SC injection Cosentyx®, Vaginal gel for prevention of urogenital chlamydia Amphora®.

Update on drugs, approval dates, and comments. Human papillomavirus (HPV) test (Cobas® HPV Test Cobas® 4800 System), Betamethasone valerate 0.12% foam (Luxiq®) are covered.

Updates on: Infliximab Remicade®Cyproterone Ethinyl Diane-35

Update on: Mupirocin calcium cream 2% Bactroban Cream® Butenafine cream Mentax®Becaplermin gel 0.01% Regranex®Finasteride 1mg tablets Propecia®Minoxidil 5% Rogaine Extra Strength for Men® Dermagraft® Graftskin® (apligraf) UV light as carcinogen

Update on Adapalene Differin® Gel 0.1%, Methyl Aminolevulinate Hydrochloride Cream Metvixia™ + Aktilite®, and Cross-linked Collagen EVOLENCE®.

Update on Quadrivalent Human Papillomavirus Recombinant Vaccine GARDASIL®, Infliximab Remicade®, Humira® Penq, and news about Malignant Melanoma and Scleroderma research.

This drug update covers Infliximab-abda for IV infusion Renflexis®, Ozenoxacin 1% cream Ozanex™, Standardized allergen extract of house dust mites sublingual tablet Acarizax®, Doxycycline hyclate immediate release tablet, and UVB Phototherapy SystemClarify™ Home Light Therapy System.

Updates on: Naturally-Derived Alpha Interferon Efavirenz Sustiva®Estradiol/Levonorgestrel Alesse®HSPPC-96 Oncophage®Tenofovir Disoproxil Fumerate Viread® Desloratidine Clarinex® 5mg. Tablets

Update on Minocycline HCl SOLODYN™ Extended Release Tablets, Linezolid ZYVOX® 600mg, Tigecycline Tygacil®, and CF-1743.

Updates on: Pimecrolimus and Tacrolimus Elidel® Cream and Protopic® Ointment Elidel®: Novartis Protopic®: Miltefosine Impavido®

Updates on: Tazarotene Tazorac® 0.1% Cream Isotretinoin Accutane®Desloratidine Clarinex® 5mg Reditabs Imiquimod Aldara®

Updates on: Alefacept AMEVIVE® Dapsone Gel 5% Aczone® Nitroglycerin Ointment Cellegesic® Cefdinir Oral Suspension Omnicef® Ultrasonic Skin Permeation Device SonoPrep® Tazarotene Capsules

Updates on: Aminolevulinic Acid Levulan® Kerastick™ photodynamic therapy Infliximab Remicade™ Butenafine HCl Mentax®Clotrimazole/Betamethasone Dipropionate

February 2013: Update on drugs, approval dates, and comments. Varicella zoster immune globulin (human) injection (Varizig®), Lidocaine 7% + tetracaine 7% cream (Pliaglis®), Isotretinoin capsule (Epuris™) are covered. Devices such as Laser hair therapy iGrow® Hair Growth Platform and LED device for acne Celluma™ are also covered.

Update on drugs, approval dates, and comments. Velaglucerase alfa (VPRIV®) and Health Canada labelling changes for isopropyl myristate 50% rinse (Resultz®, Nycomed) to include the treatment of lice in children =2 years of age are covered.

Update on: Valacyclovir HCl Valtrex®Tretinoin Gel Retin-A® Micro® Microsphere Drospirenone/Ethinyl Estradiol Yasmin®Agalsidase Beta Fabrazyme™

Update on Hyaluronic acid dermal filler + 0.3% lidocaine JUVÉDERM® XC, Hyaluronic acid dermal filler + 0.3% lidocaine RESTYLANE®-L PERLANE®-L, and news on labeling changes regarding possible hepatic effects of diclofenac sodium topical gel 1% (Voltaren® Gel).

Update on drugs, approval dates, and comments. Belimumab (Benlysta®), Adapalene 0.1% gel, Antiseborrheic compound (K301/Kaprolac®) are covered.

Update on drugs, approval dates, and comments. Collagenase clostridium histolyticum (XIAFLEX™), HPV quadrivalent recombinant vaccine (Gardasil®), Velaglucerase alfa (VPRIV™), Agalsidase alfa (REPLAGAL®), Adalimumab (Humira®) are covered.

The update covers Difelikefalin for IV use - Korsuva™ (Vifor Pharma, Cara Therapeutics), Topical MEK inhibitor - NFX-179 (NFlextion Therapeutics), Maralixibat oral solution - Livmarli™ (Mirum Pharmaceuticals), Ruxolitinib cream 1.5% - Opzelura™ (Incyte), Ruxolitinib tablets - Jakafi® (Incyte), and Avacopan capsules - Tavneos™ (ChemoCentryx).

Update on Benzyl Alcohol Lotion 5% Sciele Pharma, Red Light Technology Device + Methyl Aminolevulinate Cream Aktilite® CL 128 + Metvix®, and news Nexavar®.

Update on Bimatoprost Ophthalmic Solution 0.03% Lumigan®, Ustekinumab (CNTO-1275) Centocor, p53 tumor suppressor therapy ADVEXIN®, Shingles Vaccine Zostavax®, Calcipotriene 0.005% + betamethasone dipropionate 0.064% Xamiol® Gel, and Etanercept Enbrel®.

The latest drug & device update covers: Trifarotene 0.005% cream (Aklief®, Galderma), Afamelanotide implant (Scenesse®, Clinuvel Pharmaceuticals), Rituximab for IV use (Rituxan®, Genentech), Jynneos™ (Bavarian Nordic), Aczone® (Almirall) and Juvéderm Voluma® XC (Allergan)

Update on Bilastine tablet (Blexten™), Ixekizumab SC injection (Talz®), Wound care gel (Lasercyn™ gel), Ceftaroline fosamil (Teflaro®), Nivolumab + ipilimumab (Opdivo® + Yervoy®), PDT for actinic keratosis (Ameluz® gel + BF-RhodoLED®)

Update on: Amphotericin B Lipid Complex Injection Abelcet®Butenafine HCl Cream 1% Mentax® Itraconazole Sporanox® Acitretin Soriatane® Penciclovir cream 1% Denavir® Valacyclovir Valtrex® Laser device Sharplan Silktouch laser® Permethrin lotion Nix® Ivermectin Mectizan® (6 mg tablet)

Update on: Pimecrolimus Elidel®Butenafine HCl 1% Cream Lotrimin Ultra®Doxycycline Vibramycin®Fluocinolone acetonide Derma-Smoothe/FS®Doxycycline Thalidomid®

Update on Fluocinonide VANOS™ 0.1% Cream, Infliximab Remicade®, Tigecycline TYGACIL®, as well as drug warnings and industry news.

Update on Trametinib + Dabrafenib (Mekinist® + Tafinlar®), Tretinoin gel microsphere 0.08% (Retin-A Micro®), Fluocinonide cream 0.1%, Hydrogel wound dressing (Loutrex®), Scar treatment (Microcyn®)

Latest drug update covers Pembrolizumab, Oral JAK + SYK dual inhibitor, Lidocaine 7% + tetracaine 7% local anesthetic cream and PrabotulinumtoxinA-xvfs.

Update on Alitretinion (Toctino®), Pralatrexate, Benzyl Alcohol Lotion 5%, and Botulinum Toxin – Type A (Azzalure®) and news on Efalizumab (Raptiva®).

The update covers: Cemiplimab-rwlc for IV injection - Libtayo® (Regeneron/Sanofi), HA-based dermal filler - Restylane® Defyne™ (Galderma), Tirbanibulin ointment 1% - Klisyri® (Almirall/Athenex), Anakinra for SC use - Kineret® (Swedish Orphan Biovitrum Sobi™), Immune modulatory vaccines for melanoma - IO102 and IO103 (IO Biotech).

September-October 2017 Update on drugs include Isopropyl myristate solution Resultz®, Delafloxacin oral and IV formulations Baxdela™, Plasma-derived concentrate of C1 esterase inhibitor SC (human) Haegarda®, Oral dimethyl fumarate Skilarence®, Abatacept for IV or SC injection Orencia®, Consentyx®, Tremfya™, Yervoy® and Benlysta®.

Update on Hyaluronic Acid Gel Particles PERLANE®, Cervical Cancer Vaccine Cervarix®, Vaccinia Immune Globulin Intravenous (Human), Levocetirizine Dihydrochloride Xyzal®, and Infliximab Remicade®.

Update on drugs, approval dates, and comments. Gabapentin tablets GRALISE™(DM-1796), Oxychlorine compound (Epicyn™ HydroGel), Collagenase clostridium histolyticum (XIAPEX®) as well as drug news on HPV vaccines.